These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 15240527

  • 1. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
    Decensi A, Bonanni B, Baglietto L, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Robertson C, Marinucci I, Mariette F, Sandri MT, Daldoss C, Bianco V, Buttarelli M, Cazzaniga M, Franchi D, Cassano E, Omodei U.
    Clin Cancer Res; 2004 Jul 01; 10(13):4389-97. PubMed ID: 15240527
    [Abstract] [Full Text] [Related]

  • 2. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D, Mariani L, Mora S, Guerrieri-Gonzaga A, Cazzaniga M, Daldoss C, Ramazzotto F, Feroce I, Decensi A, Bonanni B.
    Maturitas; 2006 Aug 20; 55(1):69-75. PubMed ID: 16500052
    [Abstract] [Full Text] [Related]

  • 3. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F.
    Clin Cancer Res; 2003 Oct 15; 9(13):4722-9. PubMed ID: 14581342
    [Abstract] [Full Text] [Related]

  • 4. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
    Decensi A, Johansson H, Miceli R, Mariani L, Camerini T, Cavadini E, Di Mauro MG, Barreca A, Gonzaga AG, Diani S, Sandri MT, De Palo G, Formelli F.
    Cancer Epidemiol Biomarkers Prev; 2001 Oct 15; 10(10):1047-53. PubMed ID: 11588130
    [Abstract] [Full Text] [Related]

  • 5. Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study.
    Duschek EJ, de Valk-de Roo GW, Gooren LJ, Netelenbos C.
    Fertil Steril; 2004 Aug 15; 82(2):384-90. PubMed ID: 15302288
    [Abstract] [Full Text] [Related]

  • 6. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS, Women's Health Initiative Mammogram Density Study Investigators.
    J Natl Cancer Inst; 2005 Sep 21; 97(18):1366-76. PubMed ID: 16174858
    [Abstract] [Full Text] [Related]

  • 7. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
    Eng-Wong J, Hursting SD, Venzon D, Perkins SN, Zujewski JA.
    Cancer Epidemiol Biomarkers Prev; 2003 Dec 21; 12(12):1468-73. PubMed ID: 14693739
    [Abstract] [Full Text] [Related]

  • 8. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A, Kaushal K, Anderson S, Redpath M, Durrington PN, Selby PL, Gibson MJ.
    Gynecol Endocrinol; 2005 Mar 21; 20(3):176-82. PubMed ID: 16019358
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
    Davis SR, Stuckey BG, Norman RJ, Papalia MA, Drillich A, Bell RJ.
    Menopause; 2008 Mar 21; 15(6):1065-9. PubMed ID: 18806686
    [Abstract] [Full Text] [Related]

  • 11. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women.
    Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, Cassano E, Ramazzotto F, Baglietto L, Sandri MT, Decensi A.
    Breast Cancer Res Treat; 2008 Mar 21; 108(1):57-67. PubMed ID: 17468953
    [Abstract] [Full Text] [Related]

  • 12. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
    Nugent AG, Leung KC, Sullivan D, Reutens AT, Ho KK.
    Clin Endocrinol (Oxf); 2003 Dec 21; 59(6):690-8. PubMed ID: 14974909
    [Abstract] [Full Text] [Related]

  • 13. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.
    Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Mora S, Sandri MT, Cazzaniga M, Franchi M, Pecorelli S.
    Circulation; 2002 Sep 03; 106(10):1224-8. PubMed ID: 12208797
    [Abstract] [Full Text] [Related]

  • 14. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
    Metabolism; 2009 Jan 03; 58(1):1-7. PubMed ID: 19059524
    [Abstract] [Full Text] [Related]

  • 15. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
    Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR.
    Cancer Epidemiol Biomarkers Prev; 2003 Aug 03; 12(8):721-7. PubMed ID: 12917202
    [Abstract] [Full Text] [Related]

  • 16. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
    Ursin G, Palla SL, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Greendale GA.
    J Clin Oncol; 2004 Jul 15; 22(14):2842-8. PubMed ID: 15254051
    [Abstract] [Full Text] [Related]

  • 17. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
    Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE.
    Breast Cancer Res Treat; 2010 Apr 15; 120(2):427-35. PubMed ID: 19967558
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Conjugated estrogens and breast cancer risk.
    Campagnoli C, Ambroggio S, Biglia N, Sismondi P.
    Gynecol Endocrinol; 1999 Dec 15; 13 Suppl 6():13-9. PubMed ID: 10862264
    [Abstract] [Full Text] [Related]

  • 20. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2005 Mar 15; 20(3):144-9. PubMed ID: 16019353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.